| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 09 Nov 2026 | 10-Q |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
SAN DIEGO, November 9, 2026 — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of an investigational, potentially first-in-class WEE1 inhibitor, azenosertib, as a biomarker-dr... |
| 27 Oct 2026 | SCHEDULE 13G/A |
| 01 Oct 2026 |
Form 4: Bruns Ingmar, Chief Medical Officer
Received 9,727 shares as a grant or award ($21.2K) |
| 19 Aug 2026 | SCHEDULE 13G/A |
| 19 Aug 2026 |
Form 4: Walters Group, 10% owner and 2 others
Bought 4,335,000 shares ($15.2M) |
| 14 Aug 2026 |
8-K: Other Events
TD Securities (USA) LLCGuggenheim Securities, LLCOppenheimer & Co. Inc. |
| 14 Aug 2026 | 424B5 |
| 13 Aug 2026 | SCHEDULE 13G/A |
| 13 Aug 2026 | 424B5 |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
SAN DIEGO — August 6, 2026 — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of an investigational, potentially first-in-class WEE1 inhibitor, azenosertib, as a biomarker-dri... |
| 30 Jul 2026 | SCHEDULE 13G |
| 18 Jun 2026 |
Form 4: Johnson David Michael, Director
Received 57,100 shares as a grant or award |
| 18 Jun 2026 |
Form 4: Skvarka Jan, Director
Received 57,100 shares as a grant or award |
| 18 Jun 2026 |
Form 4: Walker Luke Nathaniel, Director
Received 57,100 shares as a grant or award |
| 18 Jun 2026 |
Form 4: Kariuki Enoch, Director
Received 57,100 shares as a grant or award |
| 18 Jun 2026 |
Form 4: Myers Scott Dunseth, Director
Received 57,100 shares as a grant or award |
Loading...